Search Results - "van Hasselt, J"

Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors by Centanni, Maddalena, Moes, Dirk Jan A. R., Trocóniz, Iñaki F., Ciccolini, Joseph, van Hasselt, J. G. Coen

“…Immune checkpoint inhibitors (ICIs) have demonstrated significant clinical impact in improving overall survival of several malignancies associated with poor…”
Get full text

Design principles of collateral sensitivity-based dosing strategies by Aulin, Linda B. S., Liakopoulos, Apostolos, van der Graaf, Piet H., Rozen, Daniel E., van Hasselt, J. G. Coen

“…Collateral sensitivity (CS)-based antibiotic treatments, where increased resistance to one antibiotic leads to increased sensitivity to a second antibiotic,…”
Get full text

Systems Pharmacology: Defining the Interactions of Drug Combinations by van Hasselt, J.G. Coen, Iyengar, Ravi

“…The majority of diseases are associated with alterations in multiple molecular pathways and complex interactions at the cellular and organ levels…”
Get full text

Predictions of Bedaquiline and Pretomanid Target Attainment in Lung Lesions of Tuberculosis Patients using Translational Minimal Physiologically Based Pharmacokinetic Modeling by Mehta, Krina, Guo, Tingjie, van der Graaf, Piet H., van Hasselt, J. G. Coen

“…Background Site-of-action concentrations for bedaquiline and pretomanid from tuberculosis patients are unavailable. The objective of this work was to predict…”
Get full text

Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity by Calizo, Rhodora C., Bhattacharya, Smiti, van Hasselt, J. G. Coen, Wei, Chengguo, Wong, Jenny S., Wiener, Robert J., Ge, Xuhua, Wong, Nicholas J., Lee, Jia-Jye, Cuttitta, Christina M., Jayaraman, Gomathi, Au, Vivienne H., Janssen, William, Liu, Tong, Li, Hong, Salem, Fadi, Jaimes, Edgar A., Murphy, Barbara, Campbell, Kirk N., Azeloglu, Evren U.

“…Nephrotoxicity is a critical adverse event that leads to discontinuation of kinase inhibitor (KI) treatment. Here we show, through meta-analyses of FDA Adverse…”
Get full text

Allele-specific collateral and fitness effects determine the dynamics of fluoroquinolone resistance evolution by Liakopoulos, Apostolos, Aulin, Linda B S, Buffoni, Matteo, Fragkiskou, Efthymia, van Hasselt, J G C, Rozen, Daniel E

“…Collateral sensitivity (CS), which arises when resistance to one antibiotic increases sensitivity toward other antibiotics, offers treatment opportunities to…”
Get full text

Transcriptomic profiling of human cardiac cells predicts protein kinase inhibitor-associated cardiotoxicity by van Hasselt, J. G. Coen, Rahman, Rayees, Hansen, Jens, Stern, Alan, Shim, Jaehee V., Xiong, Yuguang, Pickard, Amanda, Jayaraman, Gomathi, Hu, Bin, Mahajan, Milind, Gallo, James M., Goldfarb, Joseph, Sobie, Eric A., Birtwistle, Marc R., Schlessinger, Avner, Azeloglu, Evren U., Iyengar, Ravi

“…Kinase inhibitors (KIs) represent an important class of anti-cancer drugs. Although cardiotoxicity is a serious adverse event associated with several KIs, the…”
Get full text

Non‐linear blood–brain barrier transport and dosing strategies influence receptor occupancy ratios of morphine and its metabolites in pain matrix by Budda, Divakar, Gülave, Berfin, Hasselt, J. G. Coen, Lange, Elizabeth C. M.

“…Background and Purpose Morphine is important for treatment of acute and chronic pain. However, there is high interpatient variability and often inadequate pain…”
Get full text

Integrating clinical metabolomics-based biomarker discovery and clinical pharmacology to enable precision medicine by Kohler, Isabelle, Hankemeier, Thomas, van der Graaf, Piet H., Knibbe, Catherijne A.J., van Hasselt, J.G. Coen

“…Novel developments in biomarkers discovery are essential in modern health care, notably in treatment individualization and precision medicine. Clinical…”
Get full text

Predictions of Bedaquiline Central Nervous System Exposure in Patients with Tuberculosis Meningitis Using Physiologically based Pharmacokinetic Modeling by Mehta, Krina, Balazki, Pavel, van der Graaf, Piet H., Guo, Tingjie, van Hasselt, J. G. Coen

“…Background and Objective The use of bedaquiline as a treatment option for drug-resistant tuberculosis meningitis (TBM) is of interest to address the increased…”
Get full text

Model‐based dose optimization framework for bedaquiline, pretomanid and linezolid for the treatment of drug‐resistant tuberculosis by Mehta, Krina, Guo, Tingjie, Graaf, Piet H., Hasselt, J. G. Coen

“…Aims Bedaquiline, pretomanid and linezolid (BPaL) combination treatment against Mycobacterium tuberculosis is promising, yet safety and adherence concerns…”
Get full text

Biomarker‐Guided Individualization of Antibiotic Therapy by Aulin, Linda B.S., Lange, Dylan W., Saleh, Mohammed A.A., Graaf, Piet H., Völler, Swantje, Hasselt, J.G. Coen

“…Treatment failure of antibiotic therapy due to insufficient efficacy or occurrence of toxicity is a major clinical challenge, and is expected to become even…”
Get full text

Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics by Nguyen, T. H. T., Mouksassi, M‐S, Holford, N, Al‐Huniti, N, Freedman, I, Hooker, A. C., John, J., Karlsson, M. O., Mould, D. R., Pérez Ruixo, J. J., Plan, E. L., Savic, R, van Hasselt, J. G. C., Weber, B, Zhou, C, Comets, E, Mentré, F

“…This article represents the first in a series of tutorials on model evaluation in nonlinear mixed effect models (NLMEMs), from the International Society of…”
Get full text

Integrative model-based comparison of target site-specific antimicrobial effects: A case study with ceftaroline and lefamulin by van Os, Wisse, Pham, Anh Duc, Eberl, Sabine, Minichmayr, Iris K., van Hasselt, J.G. Coen, Zeitlinger, Markus

“…•We applied PK-PD modelling to compare target site-specific PK-PD of two antibiotics.•Tissue PK data, in vitro time-kill curves and MIC distributions were…”
Get full text

Virtual Patient Simulation Using Copula Modeling by Zwep, Laura B., Guo, Tingjie, Nagler, Thomas, Knibbe, Catherijne A.J., Meulman, Jacqueline J., Hasselt, J. G. Coen

“…Virtual patient simulation is increasingly performed to support model‐based optimization of clinical trial designs or individualized dosing strategies…”
Get full text

Quantitative Systems Pharmacology Modeling Framework of Autophagy in Tuberculosis: Application to Adjunctive Metformin Host-Directed Therapy by Mehta, Krina, Guo, Tingjie, Wallis, Robert S, van der Graaf, Piet H, van Hasselt, J G Coen

“…Quantitative systems pharmacology (QSP) modeling of the host immune response against Mycobacterium tuberculosis can inform the rational design of host-directed…”
Get full text

A Population Pharmacokinetic Model of Oral Docetaxel Coadministered With Ritonavir to Support Early Clinical Development by Yu, Huixin, Janssen, Julie M., Sawicki, Emilia, Hasselt, J. G. Coen, Weger, Vincent A., Nuijen, Bastiaan, Schellens, Jan H. M., Beijnen, Jos H., Huitema, Alwin D. R.

“…Oral administration of docetaxel is an attractive alternative for conventional intravenous (IV) administration. The low bioavailability of docetaxel, however,…”
Get full text

Population Pharmacokinetics of Unbound and Total Teicoplanin in Critically Ill Pediatric Patients by Aulin, L. B. S., De Paepe, P., Dhont, E., de Jaeger, A., Vande Walle, J., Vandenberghe, W., McWhinney, B. C., Ungerer, J. P. J., van Hasselt, J. G. C., De Cock, P. A. J. G.

“…Background and Objectives Teicoplanin is a highly protein-bound antibiotic, increasingly used to treat serious Gram-positive infections in critically ill…”
Get full text

Host-directed therapies for tuberculosis: quantitative systems pharmacology approaches by Mehta, Krina, Spaink, Herman P., Ottenhoff, Tom H.M., van der Graaf, Piet H., van Hasselt, J.G. Coen

“…Host-directed therapies (HDTs) that modulate host–pathogen interactions offer an innovative strategy to combat Mycobacterium tuberculosis (Mtb) infections…”
Get full text

Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel by van Hasselt, J.G.C., van Calsteren, K., Heyns, L., Han, S., Mhallem Gziri, M., Schellens, J.H.M., Beijnen, J.H., Huitema, A.D.R., Amant, F.

“…Pregnant patients with cancer are increasingly treated with anticancer drugs, although the specific impact of pregnancy-induced physiological changes on the…”
Get full text